Major interaction on record — check this product against your medications before combining. Based on 5 of 6 ingredients. Check your meds →
Dietary supplement

Anesthetized Pineapple Ingredients & Drug Interactions

by Blackstone Labs

Powder Category: Other Combinations
Most serious interaction: Major
The interaction bottom line Most serious interaction: Major

Anesthetized Pineapple is a dietary supplement by Blackstone Labs with 6 active ingredients. Its ingredients are commonly taken for exercise performance and endurance, heart health, energy support.Based on those ingredients, 1,170 medications have a known interaction with it, the most serious rated major. The ingredients most likely to interact are Valerian root extract, Gamma-Aminobutyric Acid, Phenibut. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Anesthetized Pineapple by Blackstone Labs

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 6 of its 6 active ingredients.
  • No proprietary blends here — you can verify the dose of every single component.

Anesthetized Pineapple contains 6 active ingredients: N-Acetyl L-Tyrosine, L-Taurine, Valerian root extract, Gamma-Aminobutyric Acid (GABA), Phenibut, and Mucuna pruriens (cowhage). Taurine is an amino acid your body makes; research suggests it may help with some liver conditions and heart failure, though evidence is modest.

Valerian is an herbal sedative used mainly for sleep — possibly effective for insomnia. GABA is a brain chemical that helps relax your nervous system, but evidence for supplement doses is weak.

Phenibut is a GABA-like compound with no established effectiveness and serious safety concerns in the U.S. Cowhage is a plant that naturally contains levodopa (a compound used in Parkinson's treatment) and interacts with many medications.

The product also contains inactive ingredients: maltodextrin, citric acid, erythritol, natural and artificial flavors, sucralose, and silicon dioxide.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: growth hormone stimulation, sleep, and recovery.
  • We looked for evidence on: Insomnia, Sleep deprivation, Anxiety, Stress, Postoperative recovery, Fatigue — and 4 related terms.
  • The strongest evidence on file: Valerian is rated "Possibly Effective" for Insomnia (Natural Medicines).
  • Also on file: Gamma-aminobutyric Acid (gaba) is rated "Insufficient Reliable Evidence To Rate" for Anxiety, Athletic performance, Insomnia, Post-traumatic stress disorder (PTSD).
  • Also on file: Valerian is rated "Insufficient Reliable Evidence To Rate" for Pre-procedural anxiety, Stress.

The evidence for most ingredients is limited. Taurine is possibly effective for hepatitis and congestive heart failure, but possibly ineffective for weight loss.

Valerian is possibly effective for insomnia — the strongest claim in this product — though it's not a cure. GABA, Phenibut, Cowhage, and N-Acetyl L-Tyrosine all lack reliable evidence for the conditions they're promoted for; the research isn't established in our data.

If you're considering this for sleep, valerian may help, but talk to your pharmacist about whether this combination makes sense for your needs.

The evidence, ingredient by ingredient Taurine Valerian Gamma-aminobutyric Acid (gaba) Phenibut Cowhage

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 5 of the 5 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 5 of 5.
  • General safety write-ups exist for 5 of 5.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Taurine is generally well tolerated short-term, though long-term safety is less certain; common side effects are constipation, diarrhea, and upset stomach. Rarely, taurine has been linked to allergic reactions in sensitive people.

Valerian is generally well tolerated but causes drowsiness, dizziness, and mental slowness; if you stop it after long-term use, taper slowly to avoid withdrawal symptoms like anxiety and insomnia. GABA may cause drowsiness, nausea, and muscle weakness.

Phenibut carries the highest safety concern — it's regarded as unsafe, carries a high risk of dependence and dangerous withdrawal (even after 3 days of use), and is not approved in the U.S. Cowhage can cause diarrhea, flatulence, and headache.

Taurine is rated likely safe in pregnancy and lactation; Valerian should be avoided in pregnancy and breastfeeding due to insufficient safety data. GABA, Phenibut, and Cowhage also lack adequate safety data in pregnancy and lactation and should be avoided.

Side effects, ingredient by ingredient Taurine Valerian Gamma-aminobutyric Acid (gaba) Phenibut Cowhage

Meds to double-check

Major interaction found
Known Interaction Concern · database check
Major identified

At least one ingredient has a documented Major-severity interaction. Check your medications for a personalized result.

Why this rating?
  • 5 of the 5 matched ingredients can interact with medications — Gamma-aminobutyric Acid (gaba), Valerian, Cowhage, Taurine, Phenibut.
  • The most serious interaction on file is rated Major.
  • Some involve high-stakes drug classes: diabetes medications; lithium; Parkinson's medications.
  • For scale: 1,171 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Check before use if you take blood pressure medications (especially methyldopa), monoamine oxidase inhibitors (MAOIs), levodopa, sedating drugs (CNS depressants including benzodiazepines and sleep aids), alprazolam, alcohol, diabetes medications, antipsychotics, tricyclic antidepressants, or are scheduled for certain types of anesthesia. The ingredient Phenibut also has serious risks of dependence and dangerous withdrawal that warrant extra caution.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with some supporting evidence for its stated purpose. Major medication interactions have been identified, and safety information is well characterized.

This product combines sedative and blood pressure–lowering ingredients with major interactions in several medication classes. If you take any antihypertensives, MAOIs, CNS depressants, diabetes drugs, or antipsychotics, you need to check your specific medications before use.

Phenibut's serious addiction and withdrawal risks make this formula a concern even for otherwise healthy people. Talk to your pharmacist before starting — don't use it as a substitute for prescription sleep or anxiety treatment without professional guidance.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 5 of 6 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jul 24, 2019.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Anesthetized Pineapple, straight from the product label.

Brand Blackstone Labs
Barcode (UPC) 642125502580
Net contents 9.7 oz.; 275 Gram(s)
Market status On market
Date entered into DSLD Jul 24, 2019
DSLD ID 204807
Product type Other Combinations
Supplement form Powder
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Adult (18 - 50 Years)
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Anesthetized Pineapple by Blackstone Labs, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
11 Gram(s)
Maximum serving Sizes:
11 Gram(s)
Servings per container
25
UPC/BARCODE
642125502580
IngredientAmount% DV
N-Acetyl L-Tyrosine500 mg--
L-Taurine2200 mg--
Valerian root extract250 mg--
Gamma-Aminobutyric Acid3000 mg--
Phenibut1800 mg--
Mucuna pruriens100 mg--

Other ingredients: Maltodextrin, Citric Acid, Erythritol, Natural & Artificial flavors, Sucralose, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
General Statements

Promotes growth hormone and IGF-1 stimulation Enhanced R.E.M. sleep, recovery, and rejuvenation Pharmacieutical doses of scientifically proven ingredients

Hardcore sleep formula

When you absolutely need sleep now!

25 Servings

Suggested/Recommended/Usage/Directions

Directions As a dietary supplement take (1) scoop with 8-12 oz. of water 30 minutes prior to bed time. Due to extreme potency, user may wish to begin by consuming (1/2) scoop to assess tolerance.

Precautions

Warning For use by healthy adults only, not recommended for persons under the age of 18.

Do not use if you are pregnant or nursing.

Seek advice from a healthcare professional if you have any pre-existing medical condition to ensure it is safe to take this product. In case of accidental overdose seek professional assistance or contact a poison control center immediately.

Avoid alcohol and prescription stimulants while taking this product.

Exceeding recommended serving will not improve results and may cause serious adverse health effects. Discontinue use and contact a licensed healthcare professional immediately if you experience an unusually rapid heartbeat, dizziness, severe headache, or shortness of breath.

Keep out of reach of children.

Do not use this product while operating heavy machinery.

Allergen warning: Manufactured on shared equipment that also processes eggs, wheat, & Soy (Lecithin).

FDA Disclaimer Statement

These Statements have not been evaluated by the Food and Drug Administration. This product is not intended to, treat, cure, or prevent any disease.

FDA Statement of Identity

Dietary Supplement

Formula

Naturally & Artificially Flavored

See for yourself

Anesthetized Pineapple by Blackstone Labs label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in Anesthetized Pineapple by Blackstone Labs

These are the 6 active ingredients this product is made of. Select any to open its full monograph.

Serving size11 Gram(s) Dosage formPowder Servings per container25 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

N-Acetyl L-Tyrosine

500 mg per serving

L-Taurine

Interacts with
173 drugs
2200 mg per serving

Taurine is an amino acid your body makes naturally and that you also get from animal foods. It is widely used in energy drinks and sports supplements,...

L-Taurine monograph & interactions

Valerian root extract

Interacts with
902 drugs
250 mg per serving

Valerian is an herb whose root is widely used as a natural sleep aid and for calming nerves. The evidence is mixed and often weak, so it may help some...

Valerian root extract monograph & interactions

Gamma-Aminobutyric Acid

Interacts with
419 drugs
3000 mg per serving

GABA is a calming chemical messenger (neurotransmitter) that your body makes on its own, and it is sold as a supplement for stress, anxiety, and sleep...

Gamma-Aminobutyric Acid monograph & interactions

Phenibut

Interacts with
248 drugs
1800 mg per serving

Phenibut is a synthetic, lab-made central nervous system depressant—not a natural herb—that some people use for anxiety and sleep, but it carries a se...

Phenibut monograph & interactions

Mucuna pruriens

Interacts with
193 drugs
100 mg per serving Form: L-Dopa

Cowhage (Mucuna pruriens) is a tropical legume best known as a natural source of L-dopa, the compound the body turns into dopamine. It is most studied...

Mucuna pruriens monograph & interactions

Other (inactive) ingredients: Maltodextrin, Citric Acid, Erythritol, Natural & Artificial flavors, Sucralose, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

Anesthetized Pineapple by Blackstone Labs Drug Interactions

Want to check YOUR meds against Anesthetized Pineapple?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
1,170Drugs
17 Major 658 Moderate 495 Minor

Ingredients driving the most interactions

Phenibut 248
L-Taurine 173

Each ingredient & the kinds of drugs it affects

For each ingredient in Anesthetized Pineapple with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Valerian root extract6 drug types · 902 drugs

Alcohol (Ethanol)

Valerian can have additive sedative effects when used concomitantly with alcohol.
Valerian has sedative effects. Theoretically, valerian might have an additive sedative effect when combined with alcohol. Excessive sedation has been reported in an alcohol-abusing individual who took valerian and Gingko biloba. However, the potential interaction between valerian and alcohol has been disputed in other research. Limited evidence suggests that a combination of valerian 160 mg and lemon balm 80 mg (Euvegal) does not cause further deterioration in reaction ability and reaction rate when taken with alcohol as compared to the effects of alcohol alone.

Likelihood Possible Evidence B
Alprazolam (Xanax)

Valerian can have additive sedative effects when used with alprazolam. Also, valerian in high doses might modestly increase alprazolam levels, though this is not likely to be clinically significant.
Valerian has sedative effects. Theoretically, valerian might cause additive sedation when combined with alprazolam. Also, a small pharmacokinetic study shows that taking valerian extract 1000 mg daily (providing 11 mg valerenic acid) might increase alprazolam levels by about 19%. This might be due to valerian's mild inhibition of cytochrome P450 3A4 (CYP3A4). Despite being statistically significant, this increase is not likely to be clinically significant.

Likelihood Possible Evidence B
Cns Depressants

Valerian can have additive sedative effects when used concomitantly with CNS depressant drugs.
Theoretically, concomitant use of valerian and drugs with sedative and anesthetic properties may cause additive therapeutic and adverse effects.

Likelihood Possible Evidence D
Glucuronidated Drugs

Valerian might weakly inhibit glucuronidation and increase concentrations of drugs metabolized by UGT1A1 and UGT2B7.
In vitro research shows that methanolic valerian extract and valerenic acid might competitively inhibit UDP-glucuronosyltransferase (UGT) 1A1 (UGT1A1) and UGT2B7.

Likelihood Possible Evidence D
Cytochrome P450 2D6 (Cyp2D6) Substrates

Valerian does not seem to have a clinically relevant effect on levels of drugs metabolized by CYP2D6.
Although some in vitro evidence suggests that valerian affects CYP2D6, clinical pharmacokinetic (PK) studies show that valerian is unlikely to affect the CYP2D6 enzyme. In one PK study, taking valerian 1000 mg (providing about 11 mg valerenic acid) nightly for 14 days did not affect the metabolism of dextromethorphan, a CYP2D6 substrate. In another PK study, taking valerian 125 mg three times daily for 28 days did not affect metabolism of debrisoquine, an accepted CYP2D6 probe-substrate.

Likelihood Unlikely Evidence B
Cytochrome P450 3A4 (Cyp3A4) Substrates

Valerian does not seem to have a clinically relevant effect on levels of drugs metabolized by CYP3A4.
Although some in vitro evidence suggests that valerian extract might inhibit or induce CYP3A4, clinical pharmacokinetic (PK) studies show that valerian does not have a clinically significant effect on the CYP3A4 enzyme. In one PK study, taking valerian 125 mg three times daily for 28 days did not affect metabolism of midazolam, an accepted CYP3A4 probe-substrate. In another PK study, taking valerian 1000 mg (providing about 11 mg valerenic acid) nightly for 14 days modestly increases levels of alprazolam, a CYP3A4 substrate, suggesting mild inhibition of CYP3A4. However, this mild inhibition is unlikely to be clinically relevant.

Likelihood Possible Evidence B

Gamma-Aminobutyric Acid2 drug types · 419 drugs

Antihypertensive Drugs

Theoretically, taking GABA with antihypertensive drugs might increase the risk of hypotension.
Some clinical research shows that GABA can decrease blood pressure in patients with hypertension.

Likelihood Possible Evidence B
Cns Depressants

Theoretically, GABA might have additive sedative effects when used in conjunction with CNS depressants. However, it is unclear if this concern is clinically relevant.
Endogenous GABA has well-established relaxant effects and GABA(A) receptors have an established physiological role in sleep. However, the effects of GABA supplements are unclear, as it is unknown whether exogenous GABA crosses the blood-brain barrier. Although there have been limited reports of drowsiness or tiredness with GABA supplements, these effects have not been widely reported in clinical studies. Additionally, intravenous GABA 0.1-1 mg/kg has been shown to induce anxiety in a dose-dependent manner.

Likelihood Unlikely Evidence D

Phenibut2 drug types · 248 drugs

Cns Depressants

Theoretically, phenibut might increase the risk of sedation and respiratory depression when taken with CNS depressants.
Phenibut has been associated with sedation and respiratory depression in several case reports, especially when taken at high doses.

Likelihood Possible Evidence D
Pregabalin (Lyrica)

Theoretically, phenibut might increase the risk for additive adverse effects, including sedation, when taken with pregabalin.
Phenibut is structurally related to pregabalin, and both chemicals act at GABA receptors in the brain. In a case report, a patient who had experienced tolerance to the effects of pregabalin for treatment of chronic neuropathic pain experienced a reduction in tolerance when phenibut was taken concurrently.

Likelihood Possible Evidence D

Mucuna pruriens8 drug types · 193 drugs

Levodopa

Concomitant use can increase the risk of levodopa-related adverse effects.
Cowhage contains levodopa. Some cowhage products have been standardized to contain 75-400 mg of levodopa per dose.

Likelihood Likely Evidence D
Methyldopa (Aldomet)

Theoretically, concomitant use of cowhage and methyldopa might increase the risk of hypotension.
Cowhage contains levodopa. Use of levodopa with methyldopa might cause additive hypotension. In addition, methyldopa may inhibit peripheral decarboxylation of levodopa and increase levodopa levels in the central nervous system; avoid using.

Likelihood Probable Evidence D
Monoamine Oxidase Inhibitors (Maois)

Theoretically, concomitant use of cowhage and non-selective MAOIs might increase the risk of hypertensive crisis.
Cowhage contains levodopa. Use of levodopa with non-selective MAOIs might cause hypertensive crisis. However, this interaction has not been reported with MAO-B selective inhibitors such as selegiline.

Likelihood Probable Evidence D
Anesthesia

Theoretically, concomitant use of cowhage and anesthesia might increase the risk of arrhythmias.
Cowhage contains levodopa. Use of levodopa with cyclopropane or halogenated hydrocarbon anesthesia has led to arrhythmias. Other anesthetics have not been implicated. Use other anesthetics in patients taking cowhage or tell patients to stop taking cowhage at least 2 weeks before surgery.

Likelihood Possible Evidence D
Antidiabetes Drugs

Theoretically, concomitant use of cowhage and antidiabetes drugs might increase the risk of hypoglycemia.
Animal research shows that cowhage might have hypoglycemic effects.

Likelihood Possible Evidence D
Antipsychotic Drugs

Theoretically, use of cowhage might decrease the clinical effects of antipsychotic drugs.
Cowhage contains levodopa. Use of levodopa might counteract the antidopaminergic effects of antipsychotic medications.

Likelihood Possible Evidence D
Guanethidine (Ismelin)

Theoretically, concomitant use of cowhage and guanethidine might increase the risk of hypotension.
Cowhage contains levodopa. Use of levodopa with guanethidine might cause additive hypotension; avoid using.

Likelihood Probable Evidence D
Tricyclic Antidepressants (Tcas)

Theoretically, use of TCAs might reduce the levels and clinical effects of cowhage.
Cowhage contains levodopa. Use of TCAs might reduce the absorption of levodopa. Some case reports describe patients that developed hypertension and dyskinesia when taking both levodopa and TCAs.

Likelihood Possible Evidence D

L-Taurine2 drug types · 173 drugs

Antihypertensive Drugs

Theoretically, taurine might increase the risk of hypotension when taken with antihypertensive drugs.
Some clinical evidence suggests that taurine can reduce both systolic and diastolic blood pressure.

Likelihood Probable Evidence D
Lithium

Theoretically, taurine might reduce excretion and increase plasma levels of lithium.
Taurine is thought to have diuretic properties, which might reduce the excretion of lithium.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for Anesthetized Pineapple, from the product label.

Blackstone Labs

See all Blackstone Labs products
Name
Blackstone Labs
City
Boca Raton
State
FL
ZipCode
33487
Phone Number
1-877-454-6861
Web Address
www.BlackStoneLabs.com
Pharmacist Counseling Corner

Anesthetized Pineapple by Blackstone Labs: Common Questions

Does Anesthetized Pineapple by Blackstone Labs interact with any medications?
Yes. Based on its ingredients, Anesthetized Pineapple has a known interaction with 1,170 medications, including 17 rated major. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Anesthetized Pineapple contains 6 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Is Anesthetized Pineapple safe to take if I'm pregnant or breastfeeding?
Taurine is rated likely safe in both pregnancy and breastfeeding. However, Valerian, GABA, Phenibut, and Cowhage lack sufficient safety data — the facts advise against them during pregnancy and lactation. Cowhage specifically may lower milk supply because it contains levodopa. Talk to your doctor or pharmacist before use if you're pregnant or nursing; they can help you decide if any ingredient is right for you.
Will this help me sleep?
Valerian in this product is possibly effective for insomnia — it's the strongest evidence-based ingredient here. GABA and Phenibut may have sedative effects, but their effectiveness for sleep isn't established in our data. If sleep is your goal, ask your pharmacist whether this combination is a good fit for you, especially if you take other medications.
What are the most common side effects I might experience?
Valerian commonly causes drowsiness, dizziness, and mental slowness. Taurine may cause constipation, diarrhea, or upset stomach. GABA can cause drowsiness, nausea, and muscle weakness. Phenibut carries risks of dizziness, drowsiness, nausea, and — if used for more than a few days — dangerous withdrawal. Cowhage may cause diarrhea, flatulence, and headache.
Can I stop taking this suddenly if I've been using it for a while?
No — especially if you've been taking it for more than a few days. Valerian can cause withdrawal symptoms like anxiety and insomnia if you stop abruptly; taper your dose slowly. Phenibut is even more concerning — it can cause severe withdrawal (agitation, anxiety, insomnia, seizures) after just 3 consecutive days of use and requires careful dose tapering under medical guidance. Taurine doesn't have the same withdrawal risk.
What is Phenibut and why is it in this product?
Phenibut is a GABA-like compound marketed for anxiety and cognitive function, but its effectiveness isn't established in our data. The bigger issue is that it carries a high risk of dependence, dangerous withdrawal, and overdose, and it's not approved as a supplement or drug in the U.S. Its presence in this product is a red flag — talk to your pharmacist before considering use.
Why does this product contain Mucuna pruriens (cowhage)?
Cowhage naturally contains levodopa, a compound used in Parkinson's treatment. It's marketed for anxiety, Parkinson's, and other conditions, but evidence for these uses isn't established in our data. The concern is that it interacts with many medications — especially blood pressure drugs, MAOIs, and antipsychotics — so it requires careful professional oversight. This ingredient alone makes checking with your pharmacist essential.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Anesthetized Pineapple is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Anesthetized Pineapple label
Go deeper

The Full Monographs Behind Anesthetized Pineapple’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Taurine

Interacts with 173 drugs

Taurine is an amino acid your body makes naturally and that you also get from animal foods. It is widely used in energy drinks and sports supplements, and short-term use appears generally sa...

Read the full Taurine monograph →
Herb & supplement monograph

Valerian

Interacts with 902 drugs

Valerian is an herb whose root is widely used as a natural sleep aid and for calming nerves. The evidence is mixed and often weak, so it may help some people sleep but does not work reliably...

Read the full Valerian monograph →
Herb & supplement monograph

Gamma-aminobutyric Acid (gaba)

Interacts with 419 drugs

GABA is a calming chemical messenger (neurotransmitter) that your body makes on its own, and it is sold as a supplement for stress, anxiety, and sleep. The science behind oral GABA supplemen...

Read the full Gamma-aminobutyric Acid (gaba) monograph →
Herb & supplement monograph

Phenibut

Interacts with 248 drugs

Phenibut is a synthetic, lab-made central nervous system depressant—not a natural herb—that some people use for anxiety and sleep, but it carries a serious risk of tolerance, dependence, and...

Read the full Phenibut monograph →
Herb & supplement monograph

Cowhage

Interacts with 193 drugs

Cowhage (Mucuna pruriens) is a tropical legume best known as a natural source of L-dopa, the compound the body turns into dopamine. It is most studied for Parkinson's disease symptoms and ma...

Read the full Cowhage monograph →
Sources

Sources & How We Checked

Anesthetized Pineapple's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 105 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Taurine 21 references
  1. Ahmad S, Robertson HT, Golper TA, et al. Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 1990;38:912-8. PubMed
  2. Machado-Vieira R, Viale CI, Kapczinski F. Mania associated with an energy drink: the possible role of caffeine, taurine, and inositol. Can J Psychiatry 2001;46:454-5. PubMed
  3. Obermann M, Schorn CF, Mummel P, et al. Taurine induced toxic encephalopathy? Clin Neurol Neurosurg 2006;108:812-3. PubMed
  4. Bichler, A., Swenson, A., and Harris, M. A. A combination of caffeine and taurine has no effect on short term memory but induces changes in heart rate and mean arterial blood pressure. Amino Acids 2006;31(4):471-476. PubMed
  5. Iyadurai, S. J. and Chung, S. S. New-onset seizures in adults: possible association with consumption of popular energy drinks. Epilepsy Behav 2007;10(3):504-508. PubMed
  6. Berger, A. J. and Alford, K. Cardiac arrest in a young man following excess consumption of caffeinated "energy drinks". Med J Aust. 1-5-2009;190(1):41-43. PubMed
  7. Worthley, M. I., Prabhu, A., De, Sciscio P., Schultz, C., Sanders, P., and Willoughby, S. R. Detrimental effects of energy drink consumption on platelet and endothelial function. Am J Med 2010;123(2):184-187. PubMed
  8. Morchon, Simon D. and Perez Castrillon, J. L. [Hypoglycemia by intake of taurine]. Rev.Clin Esp. 2010;210(1):49.
  9. Livshits, Z., Hoffman, R. S., Hymes, K. B., and Nelson, L. S. If vitamins could kill: massive hemolysis following naturopathic vitamin infusion. J Med Toxicol. 2011;7(3):224-226. PubMed
  10. Schoffl, I., Kothmann, J. F., Schoffl, V., Rupprecht, H. D., and Rupprecht, T. "Vodka energy": too much for the adolescent nephron? Pediatrics 2011;128(1):e227-e231. PubMed
  11. Calabro, R. S., Italiano, D., Gervasi, G., and Bramanti, P. Single tonic-clonic seizure after energy drink abuse. Epilepsy Behav 2012;23(3):384-385. PubMed
  12. Fujita, T., Ando, K., Noda, H., Ito, Y., and Sato, Y. Effects of increased adrenomedullary activity and taurine in young patients with borderline hypertension. Circulation 1987;75(3):525-532. PubMed
  13. Darling, P. B., Lepage, G., Leroy, C., Masson, P., and Roy, C. C. Effect of taurine supplements on fat absorption in cystic fibrosis. Pediatr Res 1985;19(6):578-582. PubMed
  14. Fukuyama, Y. and Ochiai, Y. Therapeutic trial by taurine for intractable childhood epilepsies. Brain Dev. 1982;4(1):63-69. PubMed
  15. Franconi, F., Bennardini, F., Mattana, A., Miceli, M., Ciuti, M., Mian, M., Gironi, A., Anichini, R., and Seghieri, G. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am.J. DOI
  16. Stohs SJ, Miller M. A case study involving allergic reactions to sulfur-containing compounds including, sulfite, taurine, acesulfame potassium and sulfonamides. Food Chem Toxicol. 2014 Jan;63:240-3. PubMed
  17. Sun Q, Wang B, Li Y, Sun F, et al. Taurine supplementation lowers blood pressure and improves vascular function in prehypertension: randomized, double-blind, placebo-controlled study. Hypertension 2016 Mar;67(3):541-9. PubMed
  18. Jang ES, Hwang SH, Kim JW, Jeong SH. Effectiveness of 4-week oral taurine treatment for muscle cramps in patients with liver cirrhosis: a single-arm pilot study. Yonsei Med J 2021;62(1):21-8. PubMed
  19. Guan L, Miao P. The effects of taurine supplementation on obesity, blood pressure and lipid profile: A meta-analysis of randomized controlled trials. Eur J Pharmacol 2020;885:173533. PubMed
  20. Higgins JP, Liras GN, Liras IN, et al. Energy Drink Effects on Hemodynamics and Endothelial Function in Young Adults. Cardiology. 2021;146(2):258-262. PubMed
  21. Pallangyo P, Bhalia SV, Komba M, et al. Acute Myocardial Infarction Following the Consumption of Energy Drink in a 28-Year-Old Male: A Case Report. J Investig Med High Impact Case Rep. 2023 Jan-Dec;11:23247096231168811. PubMed

See these in context on the Taurine monograph →

Valerian 37 references
  1. Willey LB, Mady SP, Cobaugh DJ, Wax PM. Valerian overdose: a case report. Vet Hum Toxicol 1995;37:364-5.
  2. Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on "reaction time, alertness and concentration" in volunteers. Pharmacopsychiatry 1999;32:235-41. PubMed
  3. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56:125-38. PubMed
  4. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 1999;51:505-12. PubMed
  5. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with Valerian root withdrawal. [Letter to the Editor]. JAMA 1998;280:1566-7. PubMed
  6. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000;7:273-82. PubMed
  7. MacGregor FB, Abernethy VE, Dahabra S, et al. Hepatotoxicity of herbal remedies. BMJ 1989;299:1156-7. PubMed
  8. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 1985;2:144-8. PubMed
  9. Hadley S, Petry JJ. Valerian. Am Fam Physician 2003;67:1755-8..
  10. Glass JR, Sproule BA, Herrmann N, et al. Acute pharmacological effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects. J Clin Psychopharmacol 2003;23:260-8. PubMed
  11. Lefebvre T, Foster BC, Drouin CE, et al. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharmaceut Sci 2004;7:265-73.
  12. Yuan CS, Mehendale S, Xiao Y, et al. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. Anesth Analg 2004;98:353-8. PubMed
  13. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004;32:1333-6. PubMed
  14. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005;77:415-26. PubMed
  15. Gutierrez S, Ang-Lee MK, Walker DJ, Zacny JP. Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. Pharmacol Biochem Behav 2004;78:57-64. PubMed
  16. Jacobs BP, Bent S, Tice JA, et al. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore) 2005;84:197-207. PubMed
  17. National Toxicology Program, US Department of Health and Human Services. Chemical Information Review Document for Valerian (Valeriana officinalis L.) [CAS No. 8057-49-6] and Oils [CAS No. 8008-88-6]. Supporting Nomination for Toxicological Evaluation by t
  18. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, et al. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010 Jun;11:505-11. PubMed
  19. Coxeter PD, Schluter PJ, Eastwood HL, et al. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomised n-of-1 trials. Complement Ther Med. 2003 Dec;11:215-22. PubMed
  20. Diaper A, Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res. 2004 Oct;18:831-6. PubMed
  21. Cuellar NG, Ratcliffe SJ. Does valerian improve sleepiness and symptom severity in people with restless legs syndrome? Altern Ther Health Med 2009;15:22-8.
  22. Chen D, Klesmer J, Giovanniello A, et al. Mental status changes in an alcohol abuser taking valerian and gingko biloba. Am J Addict. 2002 Winter;11:75-7. PubMed
  23. Albrecht M, Berger W, Laux P, Schmidt U, et al. Psychopharmaka und Verkehrssicherheit. Der Einfluß von Euvegal® - Dragees forte auf die Fahrtüchtigkeit und Kombinationswirkungen mit Alkohol Z Allg Med 1995;71:1215-25.
  24. Carrasco MC, Vallejo JR, Pardo-de-Santayana M, et al. Interactions of Valeriana officinalis L. and Passiflora incarnata L. in a patient treated with lorazepam. Phytother Res. 2009 Dec;23:1795-6.
  25. Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol. 2007 Nov;101:350-8.
  26. Hellum BH, Hu Z, Nilsen OG. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol. 2007 Jan;100:23-30. PubMed
  27. Alkharfy, K. M. and Frye, R. F. Effect of valerian, valerian/hops extracts, and valerenic acid on glucuronidation in vitro. Xenobiotica 2007;37(2):113-123.
  28. Vassiliadis, T., Anagnostis, P., Patsiaoura, K., Giouleme, O., Katsinelos, P., Mpoumponaris, A., and Eugenidis, N. Valeriana hepatotoxicity. Sleep Med 2009;10(8):935. PubMed
  29. Muller, Z., Sarkany, A., Altorjay, A., Szilagyi, A., Tura, T., and Ozsvar, Z. [Liver failure a la Eastern Europe]. Orv.Hetil. 3-22-2009;150(12):555-557. PubMed
  30. National Toxicology Program, US Department of Health and Human Services. Chemical Information Review Document for Valerian (Valeriana officinalis L.) [CAS No. 8057-49-6] and Oils [CAS No. 8008-88-6]. 2009;
  31. Wells SR. International intravenous administration of a crude valerian root extract. NACCT 1995;33:542.
  32. Aydinoglu U, Özcan H, Yücel A, Yücel N, Mutlu M. Valerian induced hypomania: a case report. Bull Clin Psychopharma 2012;22(Suppl. 1):S63.
  33. Mirabi P, Mojab F. The effects of valerian root on hot flashes in menopausal women. Iran J Pharm Res 2013;12(1):217-22.
  34. Thomas K, Canedo J, Perry PJ, et al. Effects of valerian on subjective sedation, field sobriety testing and driving simulator performance. Accid Anal Prev. 2016 Jul;92:240-4. PubMed
  35. Kia YH, Alexander S, Dowling D, Standish R. A case of steroid-responsive valerian-associated hepatitis. Intern Med J. 2016 Jan;46(1):118-9. PubMed
  36. Burke H, Jiang S, Chatham P, Stern TA. Delirium After Withdrawal From Valerian Root: A Case Report. Psychosomatics. 2020;61(6):787-790. PubMed
  37. Hajizadeh I, Jamshidi M, Kazemi M, Kargar H, Sadeghi T. Comparison the effect of valerian and gabapentin on RLS and sleep quality in hemodialysis patients: A randomized clinical trial. Ther Apher Dial 2023.

See these in context on the Valerian monograph →

Gamma-aminobutyric Acid (gaba) 12 references
  1. Cavagnini F, Invitti C, Pinto M, et al. Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. Acta Endocrinol (Copenh) 1980;93:149-54.
  2. Nurnberger JI Jr, Berrettini WH, Simmons-Alling S, et al. Intravenous GABA administration is anxiogenic in man. Psychiatry Res 1986;19:113-7. PubMed
  3. Gershman RN, Vasilenko MA, Iliushina GG, et al. [Gammalon in the rehabilitation in infantile cerebral palsy]. Pediatr.Akus.Ginekol. 1977;(6):26-7.
  4. Loeb C, Benassi E, Bo, GP, et al. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Epilepsy Res. 1987;1:209-12 . PubMed
  5. Inoue K, Shirai T, Ochiai H, et al. Blood-pressure-lowering effect of a novel fermented milk containing gamma-aminobutyric acid (GABA) in mild hypertensives. Eur J Clin Nutr 2003;57:490-95.
  6. ELLIOTT, K. A. and JASPER, H. H. Gammaaminobutyric acid. Physiol Rev. 1959;39(2):383-406.
  7. Winsky-Sommerer, R. Role of GABAA receptors in the physiology and pharmacology of sleep. Eur.J.Neurosci. 2009;29(9):1779-1794.
  8. Meldrum, B. S. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br.J.Clin.Pharmacol. 1989;27 Suppl 1:3S-11S. PubMed
  9. Loeb, C., Marinari, U. M., Benassi, E., Besio, G., Cottalasso, D., Cupello, A., Maffini, M., Mainardi, P., Pronzato, M. A., and Scotto, P. A. Phosphatidylserine increases in vivo the synaptosomal uptake of exogenous GABA in rats. Exp.Neurol. 1988;99(2):4 PubMed
  10. Melis, G. B., Paoletti, A. M., Mais, V., and Fioretti, P. Interference of dopamine infusion on gamma-amino butyric acid (GABA)-stimulated prolactin increase. J.Endocrinol.Invest 1980;3(4):445-448.
  11. Boonstra E, de Kleijn R, Colzato LS, Alkemade A, Forstmann BU, Nieuwenhuis S. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol. 2015 Oct 6;6:1520. doi: 10.3389/fpsyg.2015.01520. eCollection 2015. PubMed
  12. de Bie TH, Witkamp RF, Balvers MG, Jongsma MA. Effects of ?-aminobutyric acid supplementation on glucose control in adults with prediabetes: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2023;118(3):708-719. PubMed

See these in context on the Gamma-aminobutyric Acid (gaba) monograph →

Phenibut 23 references
  1. Downes MA, Berling IL, Mostafa A, Grice J, Roberts MS, Isbister GK. Acute behavioural disturbance associated with phenibut purchased via an internet supplier. Clin Toxicol (Phila). 2015;53(7):636-8. PubMed
  2. Samokhvalov AV, Paton-Gay CL, Balchand K, Rehm J. Phenibut dependence. BMJ Case Rep. 2013 Feb 6;2013. Pii: bcr2012008381.
  3. O'Connell CW, Schneir AB, Hwang JQ, Cantrell FL. Phenibut, the appearance of another potentially dangerous product in the United States. Am J Med. 2014 Aug;127(8):e3-4. PubMed
  4. Brunner E, Levy R. Case report of physiologic phenibut dependence treated with a phenobarbital taper in a patient being treated with buprenorphine. J Addict Med. 2017 May/Jun;11(3):239-40. PubMed
  5. Sankary S, Canino P, Jackson J. Phenibut overdose. AM J Emerg Med. 2017 Mar;35(3):516.e1-516.e2.
  6. Owen DR, Wood DM, Archer JR, Dargan PI. Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects, and acute toxicity. Drug Alcohol Rev. 2016 Sep;35(5):591-6. PubMed
  7. Magsalin RM, Khan AY. Withdrawal symptoms after internet purchase of phenibut (beta-phenyl-gamma-aminobutyric acid HCl). J Clin Psychopharmacol. 2010 Oct;30(5):648-9.
  8. Rod W, Kudryk A, Brunetti L, Sun N, Nguyen M. Phenibut withdrawal management in the setting of concomitant kratom and alcohol dependence. Critical Care Med 2018;46(1):451.
  9. Li W, Madhira B. Phenibut (beta-phenyl-gamma-aminobutyric acid) psychosis. Am J Therapeut 2017;24(5):e639-640.
  10. Joshi Y, Friend S, Jimenez B, Steiger L. Dissociative intoxication and prolonged withdrawal associated with phenibut: a case report. J Clin Psychopharmacol 2017;37(4):478-80. PubMed
  11. Zheng KH, Khan A, Espiridion ED. Phenibut addiction in a patient with substance use disorder. Cureus. 2019;11(7):e5230. PubMed
  12. Hardman MI, Sprung J, Weingarten TN. Acute phenibut withdrawal: A comprehensive literature review and illustrative case report. Bosn J Basic Med Sci. 2019;19(2):125-129. PubMed
  13. Ahuja T, Mgbako O, Katzman C, Grossman A. Phenibut (β-Phenyl-γ-aminobutyric Acid) dependence and management of withdrawal: Emerging nootropics of abuse. Case Rep Psychiatry. 2018;2018:9864285.
  14. Isoardi KZ, Kulawickrama S, Isbister GK. Severe phenibut poisoning: An adolescent case cluster. J Paediatr Child Health. 2020;56(2):330-331. PubMed
  15. McCabe DJ, Bangh SA, Arens AM, Cole JB. Phenibut exposures and clinical effects reported to a regional poison center. Am J Emerg Med. 2019;37(11):2066-2071. PubMed
  16. Graves JM, Dilley J, Kubsad S, Liebelt E. Notes from the field: phenibut exposures reported to poison centers - United States, 2009-2019. MMWR Morb Mortal Wkly Rep 2020;69(35):1227-8. PubMed
  17. Tamarelli C, Hosanagar A. Phenibut use in a patient prescribed gabapentinoids (letter). Pain Med 2020; Aug 4:pnaa205. doi: 10.1093/pm/pnaa205. PubMed
  18. Esposito CM, Mandolini GM, Delvecchio G, Fiorentini A, Brambilla P. Psychomotor agitation non-responsive to treatment: a case report of phenibut withdrawal syndrome. Front Psychiatry 2021;12:688147. PubMed
  19. Acosta E, Munguti C. Acute Psychosis Associated with Phenibut Ingestion. Kans J Med 2021;14:308-309. PubMed
  20. VanDreese B, Holland A, Murray A. Chronic Phenibut Use: Symptoms, Severe Withdrawal, and Recovery. WMJ 2022;121(1):E1-E4.
  21. Martin R, Buffenstein I, Cho D, Kiyokawa M. Toxidrome of an Easily Obtainable Nootropic: A Case Report of Phenibut Intoxication and Withdrawal Delirium. J Clin Psychopharmacol 2023. PubMed
  22. Morris M, Espinosa J, Lucerna A, Lahr R. A case of phenibut withdrawal and treatment with baclofen. World J Emerg Med 2023;14(4):338-340. PubMed
  23. DiFiore E, Pittman J. A Case of Phenibut Withdrawal Management and Detoxification Using Baclofen in the Outpatient Setting. Case Rep Psychiatry 2024;2024:8824770. PubMed

See these in context on the Phenibut monograph →

Cowhage 12 references
  1. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
  2. Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
  3. Anon. Epidemiological notes and reports: Mucuna pruriens-associated pruritus--New Jersey. MMWR Morb Mortal Wkly Rep 1985;34:732-3.
  4. HP-200 in Parkinson's Disease study group. An alternative medicine treatment for Parkinson's disease: Results of a multicenter clinical trial. J Alt Comp Med 1995;1:249-55. DOI
  5. Infante ME, Perez AM, Simao MR, et al. Outbreak of acute toxic psychosis attributed to Mucuna pruriens. Lancet 1990;336:1129. PubMed
  6. Vaidya AB, Rajagopalan TG, Mankodi NA, et al. Treatment of Parkinson's disease with the cowhage plant-Mucuna pruriens Bak. Neurol India 1978;26:171-6.
  7. Vadivel V, Janardhanan K. Nutritional and anti-nutritional composition of velvet bean: an under-utilized food legume in south India. Int J Food Sci Nutr 2000;51:279-87. PubMed
  8. Akhtar MS, Qureshi AQ, Iqbal J. Antidiabetic evaluation of Mucuna pruriens, Linn seeds. J Pak Med Assoc 1990;40:147-50.
  9. Prakash, D., Niranjan, A., and Tewari, S. K. Some nutritional properties of the seeds of three Mucuna species. Int.J.Food Sci.Nutr. 2001;52(1):79-82.
  10. Vadivel, V. and Janardhanan, K. Nutritional and antinutritional characteristics of seven South Indian wild legumes. Plant Foods Hum.Nutr 2005;60(2):69-75. PubMed
  11. Creapure (Creatine Monohydrate). Toxicological Datasheet. Degussa BioActives. Available at: https://www.fda.gov/ohrms/DOCKETS/.../95s-0316-rpt0154-54-Ref-50-vol112.pdf.
  12. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep 2015;5:11078. PubMed

See these in context on the Cowhage monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring